MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...

The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...

Taiho Pharma to buy next-generation ADC drug discovery company ,Araris Biotech: Japan Tuesday, March 18, 2025, 16:00 Hrs [IST] Taiho Pharmaceutical Co., Ltd., an R&D-driven specia ...

Araris is advancing three preclinical candidates for the treatment of hematological and solid tumors developed using its ...

Taiho is parting with $400 million upfront for Araris, a spin-off from the Paul-Scherrer-Institute in Zurich, Switzerland, ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...